Aspirin is frequently regarded as the prototype of a series of drugs designated non-steroidal antiinflammatory acids. There have been a succession of theories proposed to explain the anti-inflammatory action of such drugs, but generally the evidence supporting such theories has relied upon use, in vitro, of drug concentrations considerably in excess of effective therapeutic levels observed in man.
Prostaglandin Synthesis Inhibition
The discovery, in 1971, that aspirin inhibited prostaglandin (PG) synthesis ex vivo in platelets of individuals who had ingested a 600 mg dose of aspirin was therefore an especially important observation in elucidating the mode of action of this drug (Smith & Willis 1971) . This inhibition of PG synthesis is also observed in vivo in animal preparations exhibiting PG release from the spleen (Ferreira et al. 1971 ) and this action of aspirin was demonstrable in cell-free microsomal preparations whose capacity to generate PGs could be modified by aspirin concentrations within the therapeutic range (Vane 1971) . These workers observed that such inhibition was not restricted to aspii in but was also a property of other non-steroidal anti-inflammatory drugs (NSAIDs) . Subsequently, the more general theory was propounded that NSAIDs exert their anti-inflammatory action by virtue of a capacity to inhibit PG synthesis (Vane & Ferreira 1972) .
There is a body of evidence in accord with this hypothesis. Firstly, E-series PGs exert potent pharmacological actions consistent with a role as an inflammatory mediator; in man quantities as low as 1 ng administered intradermally produce distinct erythema that persists for several hours (Brocklehurst 1971) . This effect may be related to the phenomenon observed by Kaleyetal. (1972) of loss of reactivity in vessels to constrictor agents following local application of PGs. The erythema is probably accompanied by increased blood flow as is observed in the rabbit in response to picogram quantities of PGE2 (Williams 1976) . This increased blood flow is of considerable importance in determining the magnitude of inflammatory reactions and provides a plausible explanation of one mode of action of the PGs in inflammation where they can be viewed as modulators of other inflammatory agents which affect the altered permeability or porosity of vessel walls (Williams & Peck 1977) . The more labile intermediate products of arachidonic acid metabolism to PGE2 production have been proposed as likely inflammatory mediators (Kuehl et al. 1977 ), but their capacity to effect increased blood flow is less than PGE2 and the inhibition of PGE production by aspirin is accompanied by a comparable suppression of PGG2 and PGH2 formation. The second major property of PGE2 consistent with their action as inflammatory mediators is the production of hyperalgesia (Ferreira 1972) . The analysis of this phenomenon in like manner to the vasodilator properties of PGE2 is precluded by the subjective nature of pain. The use of splenic contraction as an objective index of pain in the lightly anisthetized dog was, however, consistent with this interpretation that PGE2 serves to potentiate responses to painful stimuli (e.g. intra-arterial bradykinin) (Moncada et al. 1975 ). In addition to their capacity to modify the actions of other agents that cause increased vascular permeability and pain, PGE2 does exert some direct actions of significance in chronic inflammation, namely the resorption of bone (Harris et al. 1973 ) and the stimulation of collagen secretion by fibroblasts (Peters et al. 1977) .
PGE2 can thus be seen to have a pharmacological profile appropriate to a mediator of at least certain of the features of chronic inflammation. It might appear self-evident that inhibition of PGE2 synthesis is a desirable objective and that such a property of aspirin could account for the anti-inflammatory actions of this drug. The Inhibition of PGE formation by guinea-pig macrophages estimated as concentration required to achieve 70% inhibition (Bray & Gordon, in prepration) logical extension of such reasoning would imply that other NSAIDs might supersede aspirin as the primary drug of choice in rheumatoid arthritis; yet despite their considerable potency as inhibitors of PG synthesis, many of the NSAIDs require therapeutic doses far higher than required to inhibit PG synthesis (Table 1) and aspirin remains the primary drug of choice in rheumatoid arthritis (Mills 1974) . This suggests that the capacity of NSAIDs to suppress inflammatory responses depends on properties other than inhibition of PG synthesis. This conclusion is strengthened by the emergence of NSAIDs which are effective in animal models, but which produce little inhibition of PGE synthesis (Cashin et al. 1977) , or stimulate PGE production in vitro (Bray et al. 1974) , and by the observation that in animals a deficiency in PG production following a polyunsaturated acid deficient diet, does not impair the anti-inflammatory efficacy of aspirin (Bonta et al. 1977) . The nature of the anti-inflammatory mechanism which NSAIDs may share remains enigmatic.
Recently, increased attention has been directed towards establishing the mechanism whereby lymphocyte activation results in tissue damage since thymus-dependent lymphocytes (T cells) the products of lymphocyte activation, certainly exhibit a wider range of inflammatory properties of relevance to chronic inflammation than do the prostaglandins. Thus, lymphokines may evoke increased vascular permeability, erythema, cause bone resorption, neutrophil and monocyte chemotaxis, stimulate DNA synthesis in lymphocytes and activate macrophages (Morley 1977) .
In attempting to reconcile involvement of PGs in inflammation with T cell activation, it was observed that the macrophage was a substantial source of PGE2 formation in guinea-pig inflammatory cell populations (Bray et al. 1974 ) and that lymphokine stimulated PGE2 formation in such cells ). Since PGE2 is a potent inhibitor of lymphocyte activation, this suggests that PGE2 formation by macrophages may provide a regulatory device for limiting the extent and duration of cellular immune reactions (Morley 1976) (Fig 1) . Aspirin and other NSAIDs are effective inhibitors of PG production by these cells ) whose sensitivity to indomethacin shows good agreement to that reported for human rheumatoid synovia (Kantrowitz et al. 1975 ). However, as already noted, the potency of NSAIDs as PG synthesis inhibitors would suggest a much lower therapeutic dose ratio in comparison with aspirin than clinical experience indicates. The relationship depicted in , one of which is the process of lymphocyte activation.
It is of particular interest, therefore, that of the NSAIDs, only aspirin appears capable of impairing lymphocyte activation at therapeutic concentrations (Table 1) ; the inhibition by other agents probably relating to cytotoxic effects of the drug concentrations employed. This observation is in agreement with other in vitro studies (Opelz et al. 1973 , Panush & Anthony 1976 . Perhaps of greater interest are the observations that lymphocytes collected from individuals who had ingested therapeutic doses of aspirin showed reduced reactivity to antigen or mitogen stimulation which persisted for two days following drug administration (Panush & Anthony 1976 , Crout et al. 1975 .
Future Implications
It is frequently asserted that aspirin is the primary choice of therapy in rheumatoid arthritis. This clinical assessment may reflect the capacity of therapeutic doses of aspirin not only to inhibit prostaglandin synthesis, but also to reduce the secretion of lymphokines by activated T cells in rheumatoid lesions. In the case of aspirin the inhibition of PG synthesis is particularly beneficial since the loss of PGE2 inhibition of lymphocytes is of little consequence, as aspirin can also directly inhibit lymphocyte activation. In the case of other NSAIDs, especially drugs selected as potent PG synthesis inhibitors there is the possibility that this inhibition of PG synthesis may result in symptomatic relief whilst at the same time exacerbating the release of cellular mediators of tissue change. That such a process can occur is implied by the ability of indomethacin to enhance lymphokine secretion by peripheral blood lymphocytes ). More direct evidence favouring such a hypothesis is provided by Krane and co-workers (Dayer et al. 1977 ) who showed that lymphokine stimulation of collagenase production by human rheumatoid synovia is enhanced by indomethacin whilst PGE2 production is suppressed, in agreement with predictions based upon Fig 1. The possibility thus exists that NSAIDs which are potent PG synthetase inhibitors may produce a symptomatic relief especially of vascular and pain response parameters that masks their lack of efficacy as inhibitors of lymphocyte and macrophage activation; or worse, that the PG synthesis inhibition may even accelerate the inflammatory response at the cellular level. Such a concept reconciles the contrast between efficacy of NSAIDs in acute gout as compared to rheumatoid arthritis (Sturge et al. 1977) and may explain the resilience of aspirin in rheumatoid arthritis in the face of the large number of alternative NSAIDs.
DISCUSSION
Dr Baker, MRC, Cardiff: In the trials with aspirin in the prevention of death in secondary myocardial infarction in Cardiff, from the Coronary Drug Group in the States, and more recently from Germany, there has been a reduction in deaths in the group receiving aspirin of the order of 30% -slightly higher in the German group. But the dose of aspirin ranged from 300 mg in the Cardiff trial to 1500 mg in the German trial, and Dr Loew suggested in vitro evidence of why a higher dose should be used. From a practical point of view for future trials, is there any evidence that compliance with taking different sizes of dose or a different number of tablets can be influential?
Dr Krol: We have measured compliance in both studies in the US; in the CDPA using a serotonin release test plus a urine test for salicylate. We are doing the same in AMIS using a platelet aggregation test. We find from these compliance results that they match by groups in the same way that they do on the basis of pill counts and so forth. The trouble is that compliance can be related to too many other things. People can be poor or good compliers for a variety of reasons. For instance, in the good compliance aspirin group there is no reason to believe that the good compliers in the placebo group are comparable, because there is no longer a control group. We have run into the same sort of problem with our cholesterol trials. We were asked to look at those patients whose cholesterols were reduced and compare them in two groups, but these groups were no longer comparable. So, after treatment has been started, there is no way of subdividing the patients and we avoid that.
Dr Loew: There are two factors involved. One is the pharmacological effect of ASA on platelets and the hemostatic system, and the other is compliance. In our clinical pharmacological investigations it is clear that there is a dissociation between inhibition of aggregation, inhibition of shape change and release reaction and availability. For inhibition of platelet aggregation smaller doses are effective, for inhibition of shape change two or four times that dose is needed and this is also needed to inhibit the release reaction.
In our myocardial infarction study we looked at compliance by measuring ASA blood levels and various aggregation tests. When we looked at the urine it was possible to divide subjects between aspirin takers or non-takers. Looking at the platelet test there is no difference between 100 mg and 400 mg/day, so we haven't used this test to look at compliance. I believe that the best method at the moment is to look at what happens to the release reaction and PF4 availability. We have injected volunteers with 14C ASA and measured the activity in the membrane,. and in the cytoplasm and found that the disappearance rate of labelled aspirin was a third of the known half life for the platelet, i.e. 6 to 8 days. Inhibition of the PF3 and PF4 were the same.
Dr Christine Pickard, Medical Journalist: Do your remarks about the unfortunate effects of inhibiting prostaglandin E refer to the other prostaglandins? Does this then imply that the body's ability to heal itself over a long period may be actually lessened, so that we may be increasing or prolonging the disease? Dr Morley: My remarks were directed towards E-type prostaglandins, simply because the macrophage produces that type with relatively little F-type. PGFs have little action in this system anyway. I suspect the macrophage may also produce other protaglandin compounds which may be of relevance but which we have not identified or investigated.
If E-type prostaglandins are responsible for the production of the symptoms of inflammation that are most obvious, such as erythema, pain, tenderness, swelling, then one can remove this component, but one would also be removing the beneficial effect of inhibiting lymphocyte activation. Therefore, looking for prostaglandin synthesis inhibitors alone is a scheme doomed to failure. I would suggest that a drug like aspirin has some action further up the chain of events and that in addition to inhibiting prostaglandin synthesis it can eliminate the unfortunate effects of the loss of feedback control, produced by some of these more specific compounds. These comments and thoughts were made on the basis of suggestions by clinical colleagues, who 1 think have come to this sort of conclusion for nonacademic reasons.
Dr Pickard: Would it be possible to give prostaglandin E as a treatment? The homeopaths work on the principle that something which increases the symptoms actually makes you better and it could be that PGE could also work on this principle. Dr Morley: We have considered the possibility that one could use a PGE analogue acting on the lymphocytes, which perhaps lack the properties of affecting pain receptors in vascular endothelium. That type of approach has been adopted to inhibit gastric acid secretion and 1 would suggest that it would be a sensible line to adopt to inhibit lymphocyte activation, once you recognise, accept and understand that lymphocytes are the target cells.
Sir Richard Doll: Dr Morley, can you think of any condition in which inhibition of lymphocyte multiplication might be harmful? Dr Morley: I think the interesting thing about prostaglandins is that they can readily be inhibited without any seemingly untoward effect. This would suggest that their considerable potency in controlling other physiological phenomena is not the sole control system that we utilise. It is rather like regulation of blood pressure; there have to be multiple control loops to insure against one failing. It is possible that, in certain diseases, some of these are lost and then inhibition of prostaglandin synthesis would be a rather unfortunate event.
One consequence of inhibiting lymphocyte multiplication is that if you have immune surveillance against tumours, for example, you might expect to have increased tumour incidence. However, the epidemiological studies of patients taking aspirin for rheumatoid arthritis do not indicate this, and I think the question of immune surveillance isn't quite as clear as it was thought to be, perhaps five years ago.
Dr Berkeley, Royal College of Surgeons: Dr
Morley, you said that aspirin had an effect on the activation of lymphocytes in the primary stage, and you implied that other non-steroid anti-inflammatory drugs like indomethacin perhaps did not have this effect. Have you tested that premise? Dr Morley: I did show data we have, based on doing that sort of experiment in vitro where the concentrations of non-steroidals which are needed to achieve any significant inhibition cause what I call cytopathic effects, and cannot be regarded as simple toxic effects in culture. We have not done in vivo studies which would be the next logical step, and I don't know of any good evidence from the literature that any of the non-steroidals have much effect on lymphocyte activation. I think aspirin is quite unusual in that respect.
Dr Krol: One thing I missed in Dr Loew's presentation was a total death count. One of the members of this audience said something about a 30% reduction in mortality, but I don't think that is what your figures showed. With total mortality I counted up to 27 deaths versus 32, from your data which comes to a reduction of 15.6%. Dr Loew: You must distinguish between deaths by myocardial infarction and sudden deaths. We have in the aspirin group 13 deaths, in the phenprocoumon group 26, and in the placebo group, 22. The figure of 40 or 40.9 % refers only to death due to myocardial infarction, and most of the deaths occurred in the first nine months.
Sir Richard Doll: In Dr Krol's CDPA study the 30% mortality referred to total mortality. Can you be specific about the myocardial infarction plus sudden death reduction? Dr Krol: Death from coronary heart disease would be 4.6 % in the aspirin group compared to 6.4% in the placebo. Dr Loew: Which criteria do you use for sudden deaths or myocardial infarction? Autopsy? Dr Krol: No, none of our deaths was autopsied.
Dr Loew: In our results we used autopsy, ECG and enzymes and all three points had to be positive before it was classified as death by myocardial infarction.
